FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229000937> ?p ?o ?g. }

• W4229000937 endingPage "56" @default.
• W4229000937 startingPage "45" @default.
• W4229000937 abstract "Left atrial appendage occlusion (LAAO) provides an alternative to oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation (AF). In patients with a long-term or permanent contraindication for OAC randomized controlled trial (RCT) data is lacking.To assess the efficacy and safety of LAAO in AF patients who are ineligible to use OAC. The co-primary efficacy endpoint is (1) time to first occurrence of stroke (ischemic, hemorrhagic, or undetermined) and (2) time to first occurrence of the composite of stroke, transient ischemic attack (TIA), and systemic embolism (SE). The primary safety endpoint is the 30-day rate of peri-procedural complications.This is a multicenter, investigator-initiated, open-label, blinded endpoint (PROBE), superiority-driven RCT. Patients with AF, a CHA₂DS₂-VASc score ≥2 for men and ≥3 for women and a long-term or permanent contraindication for OAC will be randomized in a 2:1 fashion to the device- or control arm. Patients in the device arm will undergo percutaneous LAAO and will receive post-procedural dual antiplatelet therapy (DAPT) per protocol, while those in the control arm will continue their current treatment consisting of no antithrombotic therapy or (D)APT as deemed appropriate by the primary responsible physician. In this endpoint-driven trial design, assuming a 50% lower stroke risk of LAAO compared to conservative treatment, 609 patients will be followed for a minimum of 1 and a maximum of 5 years. Cost-effectiveness and budget impact analyses will be performed to allow decision-making on reimbursement of LAAO for the target population in the Netherlands.The COMPARE LAAO trial will investigate the clinical superiority in preventing thromboembolic events and cost-effectiveness of LAAO in AF patients with a high thromboembolic risk and a contraindication for OAC use.NCT04676880." @default.
• W4229000937 created "2022-05-08" @default.
• W4229000937 creator A5001295240 @default.
• W4229000937 creator A5003578699 @default.
• W4229000937 creator A5004924183 @default.
• W4229000937 creator A5007982457 @default.
• W4229000937 creator A5011402757 @default.
• W4229000937 creator A5018844689 @default.
• W4229000937 creator A5020743242 @default.
• W4229000937 creator A5025799160 @default.
• W4229000937 creator A5031880700 @default.
• W4229000937 creator A5044072524 @default.
• W4229000937 creator A5045560484 @default.
• W4229000937 creator A5047243715 @default.
• W4229000937 creator A5049139322 @default.
• W4229000937 creator A5058448512 @default.
• W4229000937 creator A5064057795 @default.
• W4229000937 creator A5069495230 @default.
• W4229000937 creator A5069564198 @default.
• W4229000937 creator A5072654220 @default.
• W4229000937 creator A5076628732 @default.
• W4229000937 creator A5077862640 @default.
• W4229000937 creator A5078586706 @default.
• W4229000937 creator A5083852528 @default.
• W4229000937 creator A5084817085 @default.
• W4229000937 date "2022-08-01" @default.
• W4229000937 modified "2023-10-13" @default.
• W4229000937 title "COMPARE LAAO: Rationale and design of the randomized controlled trial “COMPARing Effectiveness and safety of Left Atrial Appendage Occlusion to standard of care for atrial fibrillation patients at high stroke risk and ineligible to use oral anticoagulation therapy”" @default.
• W4229000937 cites W1967067981 @default.
• W4229000937 cites W1999468381 @default.
• W4229000937 cites W2020074777 @default.
• W4229000937 cites W2060865513 @default.
• W4229000937 cites W2096246254 @default.
• W4229000937 cites W2097854437 @default.
• W4229000937 cites W2099710216 @default.
• W4229000937 cites W2122779695 @default.
• W4229000937 cites W2124601103 @default.
• W4229000937 cites W2136489990 @default.
• W4229000937 cites W2162508946 @default.
• W4229000937 cites W2519189161 @default.
• W4229000937 cites W2599009625 @default.
• W4229000937 cites W2766540689 @default.
• W4229000937 cites W2912139642 @default.
• W4229000937 cites W2930842499 @default.
• W4229000937 cites W2950561784 @default.
• W4229000937 cites W2970842214 @default.
• W4229000937 cites W2982536890 @default.
• W4229000937 cites W3004476220 @default.
• W4229000937 cites W3008752821 @default.
• W4229000937 cites W3013229569 @default.
• W4229000937 cites W3014781735 @default.
• W4229000937 cites W3016133011 @default.
• W4229000937 cites W3024815628 @default.
• W4229000937 cites W3035828091 @default.
• W4229000937 cites W3043037683 @default.
• W4229000937 cites W4226149068 @default.
• W4229000937 doi "https://doi.org/10.1016/j.ahj.2022.05.001" @default.
• W4229000937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35537503" @default.
• W4229000937 hasPublicationYear "2022" @default.
• W4229000937 type Work @default.
• W4229000937 citedByCount "2" @default.
• W4229000937 countsByYear W42290009372023 @default.
• W4229000937 crossrefType "journal-article" @default.
• W4229000937 hasAuthorship W4229000937A5001295240 @default.
• W4229000937 hasAuthorship W4229000937A5003578699 @default.
• W4229000937 hasAuthorship W4229000937A5004924183 @default.
• W4229000937 hasAuthorship W4229000937A5007982457 @default.
• W4229000937 hasAuthorship W4229000937A5011402757 @default.
• W4229000937 hasAuthorship W4229000937A5018844689 @default.
• W4229000937 hasAuthorship W4229000937A5020743242 @default.
• W4229000937 hasAuthorship W4229000937A5025799160 @default.
• W4229000937 hasAuthorship W4229000937A5031880700 @default.
• W4229000937 hasAuthorship W4229000937A5044072524 @default.
• W4229000937 hasAuthorship W4229000937A5045560484 @default.
• W4229000937 hasAuthorship W4229000937A5047243715 @default.
• W4229000937 hasAuthorship W4229000937A5049139322 @default.
• W4229000937 hasAuthorship W4229000937A5058448512 @default.
• W4229000937 hasAuthorship W4229000937A5064057795 @default.
• W4229000937 hasAuthorship W4229000937A5069495230 @default.
• W4229000937 hasAuthorship W4229000937A5069564198 @default.
• W4229000937 hasAuthorship W4229000937A5072654220 @default.
• W4229000937 hasAuthorship W4229000937A5076628732 @default.
• W4229000937 hasAuthorship W4229000937A5077862640 @default.
• W4229000937 hasAuthorship W4229000937A5078586706 @default.
• W4229000937 hasAuthorship W4229000937A5083852528 @default.
• W4229000937 hasAuthorship W4229000937A5084817085 @default.
• W4229000937 hasBestOaLocation W42290009371 @default.
• W4229000937 hasConcept C126322002 @default.
• W4229000937 hasConcept C127413603 @default.
• W4229000937 hasConcept C141071460 @default.
• W4229000937 hasConcept C142724271 @default.
• W4229000937 hasConcept C164705383 @default.
• W4229000937 hasConcept C168563851 @default.
• W4229000937 hasConcept C203092338 @default.
• W4229000937 hasConcept C204787440 @default.
• W4229000937 hasConcept C2776301958 @default.
• W4229000937 hasConcept C2776494729 @default.
• W4229000937 hasConcept C2779161974 @default.

• next